JAK1 and cancer: IL6 antibody siltuximab, IL6 receptor antibody tocilizumab, JAK1/2 kinase inhibitor ruxolitinib, and PD-L1 antibody (Atezolizumab, Avelumab, Durvalumab) have been approved by the FDA, simultaneously targeting both PD-1/PD-L1 and IL6/JAK1 may be more effective than single agent in cancer immunotherapy (45, 46).